Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyell Immunopharma, Inc. (Nasdaq: LYEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lyell is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its filings give structured insight into how it reports clinical, financial, and corporate developments.
Among the key documents are Current Reports on Form 8‑K, where Lyell furnishes press releases on quarterly financial results and business highlights, including updates on pivotal trials of rondecabtagene autoleucel (ronde‑cel/LYL314) in relapsed and/or refractory large B-cell lymphoma and progress in its broader CAR T-cell pipeline. Other 8‑K filings describe material agreements, such as the Exclusive License Agreement granting Lyell rights to the GCC‑targeted CAR T-cell product candidate LYL273, and a Securities Purchase Agreement for a private placement of common stock and potential pre‑funded warrants to fund pivotal-stage trials.
Filings also detail unregistered sales of equity securities related to private placements, milestone share issuances following an acquisition, and equity consideration under licensing arrangements. Additional 8‑K items cover changes in key officers, including appointments and resignations in financial leadership roles, providing context on corporate governance and management structure.
On Stock Titan, these filings are complemented by AI-powered tools that can help summarize lengthy documents, highlight items such as financing terms, licensing economics, and clinical milestone triggers, and surface relevant sections across multiple reports. Users interested in LYEL can review Forms 8‑K and other periodic reports as they become available to track how Lyell discloses clinical progress, capital structure changes, and significant agreements connected to its CAR T-cell programs.
Newton Charles W., Chief Financial Officer of Lyell Immunopharma, Inc., reported routine share sales to satisfy tax withholding on vested restricted stock units. He sold 131 shares on 08/11/2025 at a weighted average price of $10.526 (sale prices ranged $10.045–$11.00) and 136 shares on 08/12/2025 at a weighted average price of $10.338 (sale prices ranged $10.120–$10.415), for a total of 267 shares sold.
Following those transactions the filing shows beneficial ownership figures of 8,895 shares (after the 08/11 sale) and 8,759 shares (after the 08/12 sale). The report also discloses an indirect holding of 10,000 shares held by The Charles & Lisa Newton Living Trust, of which the reporting person is co-trustee and co-grantor. The filing notes 390 shares were acquired under the company ESPP on 05/18/2025 and that all share amounts reflect a 1-for-20 reverse stock split effected 05/30/2025.
Lyell Immunopharma, Inc. is a cell therapy company advancing next-generation autologous CAR T-cell product candidates for hematologic malignancies and solid tumors. On July 25, 2025, Lyell sold and issued 3,753,752 shares of common stock in a private placement at $13.32 per share pursuant to a July 24, 2025 Purchase Agreement. The Purchase Agreement provides for the potential sale of up to $50.0 million of additional common stock to the same purchasers.
This Form S-3 registers the resale of up to 3,753,752 shares issued in that private placement so the selling stockholders may sell their shares from time to time. Lyell will not receive proceeds from resales under this prospectus and has agreed to keep the registration effective until the earlier of July 25, 2028 or the date the shares are no longer registrable. The company’s common stock trades on Nasdaq Global Select Market under the symbol LYEL; the last reported sale price on August 11, 2025 was $10.58 per share. Outstanding shares used for certain calculations were 19,211,202 as of August 7, 2025.
Lyell Immunopharma reported continued clinical progress on its lead dual-targeting CD19/CD20 CAR T candidate LYL314 and detailed mid-year financials. Total assets were $385.5 million, down from $490.9 million, driven by declines in cash and marketable securities. Cash and cash equivalents stood at $98.8 million with current marketable securities of $178.0 million, and management believes available funds are sufficient to support operations at least 12 months from the issuance of these statements.
Operating results reflect ongoing development spending: six-month R&D expense was $78.3 million and net loss was $94.9 million versus $106.5 million a year earlier, while net cash used in operating activities was $89.2 million. Clinically, Lyell advanced LYL314 into the pivotal PiNACLE trial and presented Phase 1/2 data showing an 88% overall response rate and 72% complete response rate in the 3L+ cohort with median follow-up of nine months. Subsequent events include issuance of 625,000 shares to satisfy a contingent consideration milestone and a July 2025 $50.0 million gross private placement.
Lyell Immunopharma announced that it issued a press release reporting its financial results for the quarter ended June 30, 2025, and attached that release as Exhibit 99.1 to this Form 8-K. The filing states the information is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly referenced. The document also lists the company’s common stock as LYEL on the NASDAQ Global Select Market and is signed on behalf of the company by Mark Meltz, General Counsel and Corporate Secretary.
ARCH Venture Fund XIII, L.P. and affiliated entities have filed a Form 3 disclosing their initial beneficial ownership in Lyell Immunopharma (LYEL).
- Shares acquired: 938,438 common shares
- Purchase date / price: 25-Jul-2025 at $13.32 per share (per securities-purchase agreement dated 24-Jul-2025)
- Ownership status: Indirectly held through ARCH Venture Fund XIII, L.P.; the group is now classified as a 10 %+ owner under Section 16(a)
- Control structure: ARCH Venture Partners XIII, L.P. is the GP of the fund, managed by ARCH Venture Partners XIII, LLC whose investment committee members—Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis—share voting/dispositive power but disclaim beneficial ownership beyond pecuniary interest
The filing signals a sizeable insider position (≈ $12.5 million) and provides investors with updated information on Lyell’s ownership structure.
Lyell Immunopharma (Nasdaq:LYEL) filed an 8-K (Item 3.02) disclosing that the clinical milestone embedded in its October 2024 ImmPACT Bio merger has been met. The achievement obligates Lyell to issue 625,000 unregistered common shares (post 1-for-20 reverse split) to former ImmPACT securityholders in a private placement relying on the Section 4(a)(2) exemption.
The shares represent additional equity consideration; no cash will be paid. While the filing does not quantify the percentage of outstanding stock, the issuance will incrementally dilute current holders. The milestone confirms progress for ImmPACT’s next-generation CAR T-cell candidate, potentially accelerating Lyell’s cell-therapy pipeline.
- Shares are restricted and cannot be publicly resold without registration or another exemption.
- No other material items were reported.